Given that systemic treatment with CDNF reduced platelet-mediated inflammatory responses after cortical ischemic stroke, it demonstrated the capacity to decrease infarction volume, alleviate neurological deficits, and further mitigate ischemia-induced blood-brain barrier (BBB) disruption. The gene discussed is CDNF; the disease is infarction.